ANGO Stock Overview
AngioDynamics, Inc. provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
AngioDynamics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.87 |
| 52 Week High | US$11.38 |
| 52 Week Low | US$5.26 |
| Beta | 0.68 |
| 1 Month Change | 11.39% |
| 3 Month Change | -3.45% |
| 1 Year Change | -29.19% |
| 3 Year Change | -75.95% |
| 5 Year Change | -71.08% |
| Change since IPO | -53.04% |
Recent News & Updates
A Leaner AngioDynamics Is A High-Risk Execution-Driven Story
Apr 09AngioDynamics, Inc.'s (NASDAQ:ANGO) Shares Bounce 26% But Its Business Still Trails The Industry
Apr 06
Recent updates
A Leaner AngioDynamics Is A High-Risk Execution-Driven Story
Apr 09AngioDynamics, Inc.'s (NASDAQ:ANGO) Shares Bounce 26% But Its Business Still Trails The Industry
Apr 06AngioDynamics: Restructuring Initiative May Not Go Far Enough
Jan 14AngioDynamics (NASDAQ:ANGO) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Oct 12AngioDynamics (NASDAQ:ANGO) Is Carrying A Fair Bit Of Debt
Mar 31AngioDynamics Non-GAAP EPS of -$0.06 misses by $0.04, revenue of $81.5M misses by $1.93M, reaffirms FY guidance
Oct 06AngioDynamics: Lack Of Upside Capture Remains, Continue To Hold
Sep 29Is AngioDynamics (NASDAQ:ANGO) Using Debt In A Risky Way?
Sep 02AngioDynamics Non-GAAP EPS of $0.01 in-line, revenue of $87M beats by $4.09M
Jul 12AngioDynamics Shows Progress In Still-Challenging Times
Apr 08Is AngioDynamics (NASDAQ:ANGO) Using Debt Sensibly?
Apr 08AngioDynamics - Progress Despite Margin And Pandemic Challenges
Feb 01Does AngioDynamics (NASDAQ:ANGO) Have A Healthy Balance Sheet?
Jan 07Shareholders May Not Be So Generous With AngioDynamics, Inc.'s (NASDAQ:ANGO) CEO Compensation And Here's Why
Oct 28Is AngioDynamics (NASDAQ:ANGO) Weighed On By Its Debt Load?
Oct 07AngioDynamics: Focusing On Three Credible Growth Drivers And Targeting Growth Acceleration
Jul 20Shareholder Returns
| ANGO | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -7.3% | 1.8% | 1.2% |
| 1Y | -29.2% | -0.5% | 24.9% |
Return vs Industry: ANGO underperformed the US Medical Equipment industry which returned -0.7% over the past year.
Return vs Market: ANGO underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| ANGO volatility | |
|---|---|
| ANGO Average Weekly Movement | 6.8% |
| Medical Equipment Industry Average Movement | 7.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ANGO has not had significant price volatility in the past 3 months.
Volatility Over Time: ANGO's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 815 | Jim Clemmer | www.angiodynamics.com |
AngioDynamics, Inc. provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease. The company’s thrombus management portfolio includes AlphaVac system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac circuit is indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure.
AngioDynamics, Inc. Fundamentals Summary
| ANGO fundamental statistics | |
|---|---|
| Market cap | US$241.53m |
| Earnings (TTM) | -US$192.37m |
| Revenue (TTM) | US$324.01m |
0.7x
P/S Ratio-1.2x
P/E RatioIs ANGO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ANGO income statement (TTM) | |
|---|---|
| Revenue | US$324.01m |
| Cost of Revenue | US$164.37m |
| Gross Profit | US$159.64m |
| Other Expenses | US$352.01m |
| Earnings | -US$192.37m |
Last Reported Earnings
Feb 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.80 |
| Gross Margin | 49.27% |
| Net Profit Margin | -59.37% |
| Debt/Equity Ratio | 0% |
How did ANGO perform over the long term?
See historical performance and comparison